Differences in lung clearance index and functional residual capacity between two commercial multiple-breath nitrogen washout devices in healthy children and adults.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
12
09
2019
accepted:
07
04
2020
entrez:
3
7
2020
pubmed:
3
7
2020
medline:
3
7
2020
Statut:
epublish
Résumé
Multiple-breath nitrogen washout (MBNW) and its clinical parameter lung clearance index (LCI) are gaining increasing attention for the assessment of small airway function. Measurement of LCI relies on accurate assessment of functional residual capacity (FRC). The EasyOne Pro LAB (ndd) and Exhalyzer D (EM) are two commercially available MBNW devices. The aim of the study was to compare these two devices
Identifiants
pubmed: 32613018
doi: 10.1183/23120541.00247-2019
pii: 00247-2019
pmc: PMC7322914
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©ERS 2020.
Déclaration de conflit d'intérêts
Conflict of interest: A.M. Zwitserloot reports a grant from Stichting Astma Bestrijding and that ndd Medical Technologies provided the EasyOne Pro LAB MBNW device and lung model setup for this study; and money to her institution for an advisory board for GSK outside the submitted work. Conflict of interest: E.J. van den Berg has nothing to disclose. Conflict of interest: L.H.A. Raaijmakers has nothing to disclose. Conflict of interest: W.E. Stalman has nothing to disclose. Conflict of interest: M. van Smaalen has nothing to disclose. Conflict of interest: M. van den Berge reports research grants to his university from GlaxoSmithKline, TEVA, Chiesi and Novartis, outside the submitted work. Conflict of interest: M. Gappa has nothing to disclose. Conflict of interest: G.H. Koppelman reports grants from the Lung Foundation of the Netherlands during the conduct of the study, TETRI Foundation, UBBO EMMIUS Foundation, TEVA the Netherlands, VERTEX and GSK, and that he has participated in an advisory board for GSK, outside the submitted work. Conflict of interest: B.W.M. Willemse has nothing to disclose.
Références
Eur Respir J. 2005 Sep;26(3):511-22
pubmed: 16135736
ERJ Open Res. 2017 Oct 02;3(4):
pubmed: 29204436
J Cyst Fibros. 2014 Mar;13(2):190-7
pubmed: 24075581
J Cyst Fibros. 2017 Nov;16(6):e22-e23
pubmed: 28185888
Am J Respir Crit Care Med. 2007 Nov 1;176(9):858-64
pubmed: 17702968
Am J Respir Crit Care Med. 2008 Jul 1;178(1):42-9
pubmed: 18403721
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
PLoS One. 2014 Jun 03;9(6):e98487
pubmed: 24892522
Thorax. 2004 Dec;59(12):1068-73
pubmed: 15563707
Respir Physiol Neurobiol. 2005 Aug 25;148(1-2):125-39
pubmed: 15993657
Thorax. 1999 Apr;54(4):329-33
pubmed: 10092694
Ann Am Thorac Soc. 2015 Jun;12(6):932-9
pubmed: 26075554
Eur Respir J. 1998 Jan;11(1):246-55
pubmed: 9543301
J Appl Physiol (1985). 2002 Feb;92(2):634-42
pubmed: 11796675
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
Eur Respir J. 2013 Mar;41(3):507-22
pubmed: 23397305
Thorax. 2012 Oct;67(10):874-81
pubmed: 22752198
Thorax. 2012 Sep;67(9):789-95
pubmed: 22544894
Respirology. 2015 Apr;20(3):459-66
pubmed: 25605535
Eur Respir J. 2003 Dec;22(6):972-9
pubmed: 14680088
J Cyst Fibros. 2017 Mar;16(2):258-266
pubmed: 27919570
Pediatr Pulmonol. 2010 Feb;45(2):107-17
pubmed: 20082341
Am J Respir Crit Care Med. 2005 Feb 15;171(4):371-8
pubmed: 15531750
Am J Respir Crit Care Med. 2002 Jan 1;165(1):83-7
pubmed: 11779735
Respir Med. 2014 Jun;108(6):865-74
pubmed: 24726097
Pediatr Pulmonol. 2012 Jul;47(7):649-57
pubmed: 22170866
PLoS One. 2012;7(4):e36083
pubmed: 22558338
J Cyst Fibros. 2014 Mar;13(2):123-38
pubmed: 24315208
PLoS One. 2013;8(2):e56868
pubmed: 23457632
J Appl Physiol (1985). 1985 Sep;59(3):838-46
pubmed: 4055573
Respir Med. 2016 Mar;112:59-64
pubmed: 26856191
Curr Opin Pulm Med. 2012 Jan;18(1):23-8
pubmed: 22113001
J Pediatr. 2004 Feb;144(2):154-61
pubmed: 14760252